Oppenheimer Asset Management Inc. bought a new position in Qiagen N.V. (NASDAQ:QGEN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,941 shares of the company’s stock, valued at approximately $114,000.
Other institutional investors also recently made changes to their positions in the company. Quadrant Capital Group LLC boosted its position in shares of Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock worth $154,000 after buying an additional 4,421 shares in the last quarter. Rehmann Capital Advisory Group bought a new position in shares of Qiagen N.V. during the first quarter worth approximately $207,000. Prudential Financial Inc. bought a new position in shares of Qiagen N.V. during the first quarter worth approximately $207,000. M&T Bank Corp bought a new position in shares of Qiagen N.V. during the first quarter worth approximately $230,000. Finally, Wetherby Asset Management Inc. boosted its position in shares of Qiagen N.V. by 1.8% in the first quarter. Wetherby Asset Management Inc. now owns 9,273 shares of the company’s stock worth $269,000 after buying an additional 163 shares in the last quarter. 61.03% of the stock is currently owned by institutional investors.
Shares of Qiagen N.V. (NASDAQ QGEN) opened at 34.07 on Monday. Qiagen N.V. has a 12-month low of $22.80 and a 12-month high of $35.26. The company has a market capitalization of $7.76 billion, a PE ratio of 94.64 and a beta of 1.15. The firm’s 50-day moving average price is $33.63 and its 200-day moving average price is $30.30.
A number of equities analysts recently commented on QGEN shares. TheStreet raised Qiagen N.V. from a “c” rating to a “b” rating in a report on Monday, June 5th. Commerzbank Ag reaffirmed a “buy” rating on shares of Qiagen N.V. in a report on Monday, May 29th. Barclays PLC reaffirmed a “buy” rating and issued a $33.00 target price on shares of Qiagen N.V. in a report on Monday, May 15th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen N.V. in a report on Tuesday, May 2nd. Finally, BidaskClub cut Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 10th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $29.56.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).
What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.